Keryx Rises as Phase III Zerenex Study Readies to Leave the Gate - BioWorld Online PDF Print
BioWorld OnlineBentsur insisted that the drug has shown clear factors that differentiate it from currently marketed medicines to treat hyperphosphatemia in ESRD patients ...Keryx Biopharmaceuticals Initiates Phase 3 Registration Program Of Zerenex

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.